[go: up one dir, main page]

MX2020009682A - Vacunas de nanoparticulas multivalentes contra la influenza. - Google Patents

Vacunas de nanoparticulas multivalentes contra la influenza.

Info

Publication number
MX2020009682A
MX2020009682A MX2020009682A MX2020009682A MX2020009682A MX 2020009682 A MX2020009682 A MX 2020009682A MX 2020009682 A MX2020009682 A MX 2020009682A MX 2020009682 A MX2020009682 A MX 2020009682A MX 2020009682 A MX2020009682 A MX 2020009682A
Authority
MX
Mexico
Prior art keywords
influenza
vaccines against
against influenza
disclosed
multivalent
Prior art date
Application number
MX2020009682A
Other languages
English (en)
Inventor
Gale Smith
Sarathi Boddapati
Anushree Herwadkar
Jason Wong
Yen - Huei Lin
Jing - Hui TIAN
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2020009682A publication Critical patent/MX2020009682A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen composiciones de vacuna de nanopartículas multivalentes adecuadas para su uso en vacunas contra la influenza. Las nanopartículas incluyen cantidades eficaces de glicoproteínas de la influenza que proporcionan una mayor respuesta inmunitaria en comparación con una composición de vacuna contra la influenza disponible comercialmente. La presente descripción también proporciona estrategias de formulación de vacunas que son rentables y convenientes para uso clínico. También se describen métodos para administrar las composiciones de vacuna de nanopartículas a un sujeto.
MX2020009682A 2018-03-19 2019-03-19 Vacunas de nanoparticulas multivalentes contra la influenza. MX2020009682A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644623P 2018-03-19 2018-03-19
US201962787980P 2019-01-03 2019-01-03
PCT/US2019/022930 WO2019183063A1 (en) 2018-03-19 2019-03-19 Multivalent influenza nanoparticle vaccines

Publications (1)

Publication Number Publication Date
MX2020009682A true MX2020009682A (es) 2020-10-12

Family

ID=67987992

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009682A MX2020009682A (es) 2018-03-19 2019-03-19 Vacunas de nanoparticulas multivalentes contra la influenza.
MX2020011712A MX2020011712A (es) 2018-03-19 2020-09-17 Vacunas de nanoparticulas multivalentes contra la influenza.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011712A MX2020011712A (es) 2018-03-19 2020-09-17 Vacunas de nanoparticulas multivalentes contra la influenza.

Country Status (12)

Country Link
US (3) US11278612B2 (es)
EP (1) EP3768308A4 (es)
JP (1) JP7417532B2 (es)
KR (2) KR20210004959A (es)
CN (2) CN112469436B (es)
AU (2) AU2019238171B2 (es)
BR (1) BR112020019108A2 (es)
CA (1) CA3092984A1 (es)
IL (2) IL305911B2 (es)
MX (2) MX2020009682A (es)
SG (1) SG11202009206QA (es)
WO (1) WO2019183063A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667355B1 (ko) 2015-09-03 2024-05-20 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
ES3028362T3 (en) 2017-07-24 2025-06-19 Novavax Inc Methods and compositions for treating respiratory disease
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
US20230256082A1 (en) 2020-04-24 2023-08-17 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
MX2023013081A (es) * 2021-05-05 2024-01-15 Novavax Inc Composiciones de coronavirus e influenza y métodos para utilizarlas.
WO2025088585A1 (en) * 2023-10-25 2025-05-01 Novavax AB Saponin-based adjuvants and methods of characterizing same
WO2025101668A1 (en) * 2023-11-06 2025-05-15 Novavax, Inc. Intranasal immunogenic compositions

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
NZ525076A (en) 2000-10-02 2004-09-24 Glaxosmithkline Biolog S A split enveloped RSV virus vaccine fomulation
SE0201750D0 (sv) 2002-06-06 2002-06-06 Chalmers Technology Licensing Selective Chromophores
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
KR20110097971A (ko) 2003-04-25 2011-08-31 메디뮨 백신즈, 인코포레이티드 메타뉴모바이러스 유래 이종 항원을 포함하는 재조합 파라인플루엔자 바이러스 발현 시스템 및 백신
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2005080417A2 (en) 2003-12-10 2005-09-01 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
CA2585859C (en) 2004-10-29 2012-03-06 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US20070292386A9 (en) 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
US8425915B2 (en) 2006-04-13 2013-04-23 Midatech Limited Nanoparticles for providing immune responses against infectious agents
EP2040746A4 (en) 2006-06-19 2009-12-16 Progenics Pharm Inc METHODS OF RECOVERING STABILIZED FORMULATIONS OF RETROVIRAL ENVELOPE (ENV) PROTEIN TRIMERS
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
WO2008068631A2 (en) * 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008114149A2 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
ES2542644T3 (es) 2007-07-19 2015-08-07 Novavax, Inc. VLPS quiméricas de la gripe aviar
SG185294A1 (en) * 2007-10-12 2012-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
EP2207558A1 (en) 2007-11-06 2010-07-21 Massachusetts Institute of Technology Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
CN102014873A (zh) 2008-02-25 2011-04-13 诺瓦瓦克斯股份有限公司 糖玻璃化的病毒样颗粒
RU2531510C2 (ru) 2008-12-09 2014-10-20 Новавакс, Инк. Модифицированные f протеины sv и способы их применения
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
MX357630B (es) 2009-05-27 2018-07-17 Selecta Biosciences Inc Nanoportadores sintéticos objetivo con liberación sensible al ph de agentes inmunomoduladores.
CN102470168A (zh) 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
ES2918381T3 (es) 2009-07-15 2022-07-15 Glaxosmithkline Biologicals Sa Composiciones de proteína F de VRS y métodos para producir las mismas
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
KR101847908B1 (ko) 2010-11-05 2018-04-11 노바백스, 인코포레이티드 광견병 당단백질 바이러스-유사 입자(VLPs)
CN102107003A (zh) 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
MX2014003777A (es) 2011-09-30 2015-05-15 Novavax Inc Vacuna de nanoparticulas de proteinas f del rsv recombinantes para el virus respiratorio sincitial.
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
JP2016509015A (ja) 2013-02-11 2016-03-24 ノババックス，インコーポレイテッド 呼吸器合胞体ウイルス及びインフルエンザ用の混合ワクチン
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
WO2015042373A1 (en) 2013-09-19 2015-03-26 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
CN104740609A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的药物组合物
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
US20160045574A1 (en) 2014-08-18 2016-02-18 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
EP4019044A3 (en) 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
KR102667355B1 (ko) 2015-09-03 2024-05-20 노바백스, 인코포레이티드 개선된 안정성 및 면역원성을 갖는 백신 조성물
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
IL306088A (en) * 2021-03-22 2023-11-01 Novavax Inc Vaccine formulations against coronavirus

Also Published As

Publication number Publication date
WO2019183063A1 (en) 2019-09-26
IL305911A (en) 2023-11-01
CN112469436B (zh) 2025-03-14
BR112020019108A2 (pt) 2020-12-29
IL305911B1 (en) 2024-09-01
EP3768308A1 (en) 2021-01-27
JP7417532B2 (ja) 2024-01-18
US20190314487A1 (en) 2019-10-17
AU2019238171A1 (en) 2020-09-24
MX2020011712A (es) 2021-01-08
KR20210004959A (ko) 2021-01-13
US11896662B2 (en) 2024-02-13
CA3092984A1 (en) 2019-09-26
CN120227451A (zh) 2025-07-01
IL277274B2 (en) 2024-02-01
US20220080039A1 (en) 2022-03-17
US11278612B2 (en) 2022-03-22
CN112469436A (zh) 2021-03-09
KR20250151575A (ko) 2025-10-21
EP3768308A4 (en) 2022-01-26
IL305911B2 (en) 2025-01-01
IL277274A (en) 2020-10-29
IL277274B1 (en) 2023-10-01
RU2020130610A (ru) 2022-03-17
AU2019238171B2 (en) 2026-01-08
AU2025275176A1 (en) 2026-01-15
JP2021518353A (ja) 2021-08-02
SG11202009206QA (en) 2020-10-29
US20240293530A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
MX2020009682A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
PH12017501321A1 (en) Oral care compositions and methods of use
BR112017001796A2 (pt) composições de flagelina e seus usos
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
CR10559A (es) Vacuna de influenza
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2013012219A (es) Método de administración de vacunas.
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
UY36395A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
MX392862B (es) Formulación de vacuna contra el vih.
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
MX2021006021A (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
MX2025002465A (es) Metodos y dispositivos para la preparacion de agentes de contraste de ultrasonido
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201592003A1 (ru) Микропищевые добавки для иммунитета
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela